Carrier-bound Methotrexate. IV. Antiproliferative Activity of Polyaspartamide-MTX Conjugates against Leukemic Lymphoblast Cell Lines by N’Da, DD et al.
Carrier-bound Methotrexate. IV. Antiproliferative Activity of
Polyaspartamide-MTX Conjugates against Leukemic
Lymphoblast Cell Lines
David D. N’Da,a Eberhard W. Neusea* and Constance E.J. van Rensburgb
aSchool of Chemistry, University of the Witwatersrand, WITS, 2050 South Africa.
bDepartment of Pharmacology, Faculty of Medicine, University of Pretoria, P.O. Box 2034, Pretoria, 0001 South Africa.
Received 17 May 2005; revised and accepted 7 November 2006.
ABSTRACT
Polymeric conjugates of methotrexate (MTX) with macromolecular carriers, obtained from amine-functionalized polyaspar-
tamides by coupling with one of the drug’s carboxyl groups, are used in this preliminary screening project for in vitro cytotoxicity
assessment. The water-soluble conjugates, crudely fractionated by aqueous dialysis, possess mass-average molecular masses in
the range of 20000–30000. Screens are performed by standard procedures against cultured CEM/S human leukemic lymphoblast
cells, a drug-sensitive line, and against CEM/E, its drug-resistant subline, for comparison also against unconjugated MTX. All
compounds tested, including the unconjugated drug, display decreasing activity on going from CEM/S to CEM/E, resistance
factors (IC50 [CEM/E]/IC50[CEM/S]) being in the vicinity of 15–20 for MTX as well as for the majority of conjugates. On the other
hand, comparisons of IC50 values for conjugates versus free drug, both against CEM/S and CEM/E, show vastly superior
antiproliferative performance of the drug in the carrier-anchored state over the free form, with activity factors (IC50[free
MTX]/IC50 [conjugate]) typically in the 10–50 range and higher. On the basis of these promising in vitro findings, the
polyaspartamide-MTX conjugates are considered to be excellent candidates for further cell culture and extended in vivo tests.
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1. Introduction
For several decades now, the antifolate drug methotrexate
(+ amethopterine, MTX), a classical, highly potent anticancer
agent, has been in clinical use both per se and in combination
with other drugs.2–4 The compound acts as an inhibitor of
dihydrofolate reductase, thus preventing the reduction of
7,8-dihydrofolate to 5,6,7,8-tetrahydrofolate. This leads to inhi-
bition of DNA synthesis and eventual cell death.3
To the detriment of patient compliance, however, the drug
suffers from severe pharmacological shortcomings, notably high
systemic toxicity and a propensity for eliciting drug resistance
in the affected cells.4,5 In efforts to enhance the compound’s
therapeutic effectiveness, numerous laboratories worldwide
have embarked on projects aiming at the bioreversible attach-
ment (conjugation) of the drug to biocompatible carrier poly-
mers that would serve as vehicles capable of enhancing bio-
availability while circumventing the toxicity and resistance
problems. Here we cite only the pioneering work by Ringsdorf6
and, later, by Shen and Ryser.7
In our laboratory, synthetic polymers have been given preference
over natural macromolecules as carriers for drug anchoring.
This choice is based on the lower immunogenicity generally
shown by suitably constructed synthetics, paired with the over-
riding advantage that a synthetic polymer may be tailor-made to
accord with biomedical specifications and unique compositional
requirements. Thus, ‘blueprints’ for the structural build-up of
both the hydrosolubilizing and the drug-binding subunits, as
well as their relative frequencies along the backbone, can be
predetermined and synthetically executed. Such structural
versatility is strikingly displayed by peptidic polymers of the
,-DL-polyaspartamide type, and we have used these exten-
sively for drug conjugation.8 The inclusion of -peptidic and
D-configurated units in the main chain prevents rapid
exopeptidase-mediated degradation through ‘unzipping’, thus
ensuring sufficient stability of the conjugate while in central
circulation. In an earlier project in this laboratory9 poly-
aspartamides were conjugated with MTX through tethers
containing an ester group as the biofissionable site, and in a
recent study1 we prepared a series of related conjugates with
biocleavable carboxamide links in the connecting spacer
(Scheme 1; for convenience, only the -form is depicted here).
Representative conjugates of both classes have now entered
preliminary in vitro screening studies, in which their anti-
proliferative properties are assayed against a series of human
cancer cell lines. In the present communication we present the
screening results obtained with selected conjugates containing
amide-tethered MTX against human CEM/S leukemic
lymphoblasts and the derived multidrug-resistant CEM/E
subline. It has been our special objective in this study to compare
these results with the cytotoxic behaviour of free, i.e. unconju-
gated MTX tested in the same screens.
2. Results and Discussion
It was demonstrated in the preceding investigation1 that MTX
can be conjugated in aprotic medium with polyaspartamides
bearing short, amine-terminated side chains, as depicted in
Scheme 1. The reactions are mediated by coupling agents, such
as HBTU, (2-(1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate) or EEDQ, 1-ethoxycarbonyl-2-ethoxy-
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1,2-dihydroquinoline. This coupling technique was employed
with minor modifications for the preparation of most of the
conjugates used in the present project, while a few more conju-
gates were taken from that earlier work.1 The drug is carrier-
bound in these reactions through one of its carboxyl groups, the
-COOH functionality being the preferred one in view of its
higher reactivity.10 We used a 20–30% molar excess of MTX and
coupling agent in order to enforce acceptable drug incorpora-
tion, but even under these facilitating conditions complete
acylation of available NH2 groups was not always achieved; in
the majority of reactions, product polymers tended to be a few
per cent short of complete acylation. In exceptional cases, where
drug incorporation remained below 90%, the products were
retreated with MTX and coupling agent, which brought the
extent of N-acylation up to an acceptable level of 95% or higher.
The collection of conjugates made available for testing is
reproduced in Fig. 1, and compositional data are collected in
Table 1. Whereas in compounds 1 to 8 the hydrosolubilizing
functionality R1 is represented by a tertiary amine side chain
terminal acting as a potentially cationic species on protonation
under physiological conditions, conjugate 9 features an indiffer-
ent methoxy side group terminal, and in 10 to 14 the group R1 is
represented by a hydroxyl-terminated alkyl chain.
The conjugates were tested in vitro by standard procedure11
against the drug-sensitive CEM/S cell line and, in parallel,
against the multidrug-resistant CEM/E subline. Free MTX was
tested under the same conditions for comparison. The cytotoxic
activities determined for the individual samples are listed in
Table 2, expressed in terms of IC50 values (drug concentration,
in µg MTX mL–1, required to retain 50% cell viability relative to
drug-free control). The table also contains entries for the resis-
tance factor, RF, defined here as the ratio of IC50[CEM/E] over
IC50[CEM/S].
A cursory comparison of the results tabulated in the two CEM
columns immediately reveals the expected trend of lowered
activity on going from CEM/S to CEM/E, with resistance factors
generally in the vicinity of 15–20, and the same trend obtains for
free MTX (RF = 20.5). Against the two CEM lines, then, the
carrier-bound drug, on balance, exhibits no selective ability to
circumvent resistance. For conjugates 3 and 8 resistance factors
below 5 are apparent from the tabulation. These are exceptional,
however, and a larger number of repetitively synthesized conju-
gates will be required to confirm and rationalize this deviating
behaviour.
Comparing now performance data of individual conjugate
structures, we detect only minor differences on going from type
to type. Significantly, against CEM/S, the overall IC50 range
(~0.01–0.2) for polymers with tertiary amine side functionalities
(1 to 8) does not substantially differ from that (~0.01–0.3) deter-
mined for the conjugates featuring hydroxyl-terminated side
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groups (10 to 14). The same argument holds for the IC50 data
determined against CEM/E. (The only outstanding case is
conjugate 9, which shows poor performance relative to all other
samples; this may be an artifact, however, which will be reinves-
tigated). Evidently, realistic structure-performance relation-
ships can only be derived on the basis of an increased sample
number for each structural type, and future investigations will
focus on this topic.
The most striking aspect of the here described series of tests
emerges as we compare for each CEM column the data derived
for the carrier-drug conjugates with those pertaining to
unconjugated MTX. With just one exception (conjugate 9), the
conjugate-derived IC50 values are considerably lower than the
respective values for the free drug. This indicates the cytotoxic
activities of the polymer-bound drug to exceed monomeric MTX
activity by a large factor (40- to 50-fold in about one-third of all
tested samples). The tabulated figures in the activity factor
column (AF = IC50[MTX]/IC50 [conjugate]) provide the details.
In summary: methotrexate, both conjugated and non-
conjugated, shows essentially the same trend of decreasing
antiproliferative activity on going from the sensitive to the
resistant CEM lines. Conjugation thus provides no panacea for
circumvention of drug resistance in tests against CEM. On the
other hand, vastly superior activities, up to 50-fold and higher,
against both CEM/S and CEM/E are observed for the carrier-
anchored MTX derivatives in relation to the unbound drug. In
view of the common experience that realistic pharmacological
benefits, as they arise from drug binding to a carrier polymer,
will manifest themselves predominantly, if not solely, in the
living organism,12–14 these findings are highly significant and
warrant ongoing studies involving further synthetic work and
extensive in vitro/in vivo screens.
3. Experimental
3.1. General Procedures
Inherent viscosities, ηinh , were determined with the aid of
Cannon-Fenske viscometers in H2O at 30.0 ± 0.5°C; the concen-
tration was c = 0.2 g100 mL–1. Data are reported in units of dL g–1.
1H NMR spectra (400 MHz; integration error limits, ± 12%) were
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Table 1 Structural data for conjugates 1 to 14.
Conjugate designation Base molecular mass a ηinh /mL g
–1 Extent of acylation b % MTX by mass
1 4393.4 101 10.4
2 2387.8 16.2 97 18.5
3 1382.8 20.0 95 31.2
4 2466.3 15.4 98 18.1
5 4400.6 95 9.8
6 2429.9 16.8 101 18.7
7 1411.9 20.2 95 30.6
8 2408.2 98 18.5
9 2186.3 13.9 100 20.8
10 3615.52 18.6 94 11.8
11 2047.0 97 21.5
12 4474.3 99 10.0
13 2456.6 100 18.5
14 2405.7 95 17.9
a Molecular mass of recurring unit.
b Percentage substitution by MTX of available NH2.
TABLE 2 Antiproliferative activity of conjugates 1 to 14 against CEM/S and CEM/E.




µg MTX mL–1 M c µg MTX mL–1 M c
1 0.023 5.06 × 10–8 36.3 0.548 1.21 × 10–6 31.1 23.8
2 0.107 2.35 × 10–7 7.8 1.556 3.42 × 10–6 11.0 14.5
3 0.137 3.01 × 10–7 6.1 0.542 1.19 × 10–6 31.5 4.0
4 0.163 3.59 × 10–7 5.1 2.120 4.67 × 10–6 8.1 13.0
5 0.016 3.52 × 10–8 52.1 0.331 7.28 × 10–7 51.6 20.7
6 0.121 2.66 × 10–7 6.9 1.773 3.90 × 10–6 9.6 14.7
7 0.02 4.40 × 10–8 41.7 0.467 1.03 × 10–6 36.5 23.4
8 0.145 3.19 × 10–7 5.8 0.633 1.39 × 10–6 27.0 4.4
9 >20 >4.4 × 10–5 – >20 >4.4 × 10–5 – –
10 0.031 6.82 × 10–8 26.9 0.577 1.27 × 10–6 29.6 18.6
11 0.273 6.01 × 10–7 3.1 6.433 1.42 × 10–5 2.7 23.6
12 0.019 4.18 × 10–8 43.9 0.377 8.30 × 10–7 45.3 19.8
13 0.013 2.86 × 10–8 64.1 0.281 6.18 × 10–7 60.7 21.6
14 0.011 2.42 × 10–8 75.8 0.228 5.02 × 10–7 74.9 20.7
MTX 0.834 1.84 × 10–6 – 17.07 3.76 × 10–5 – 20.5
a Activity factor: IC50[free MTX]/IC50[conjugate].
b Resistance factor: IC50[CEM/E]/IC50[CEM/S].
c Moles MTX/L.
taken on D2O solutions. Chemical shifts, , are given in ppm
relative to sodium 3-(trimethylsilyl)-2,2,3,3-d4-propionate;
unless stated otherwise, D2O solutions of polymeric materials
were routinely adjusted to pD 10 just prior to scanning to
eliminate spurious protonation. A VIRTIS Bench Top 3 freeze-
drier operating at –30°C, 0.1 torr, was used for the lyophilization
of aqueous polymer solutions. Dialysis was performed in
Spectra/Por 4 membrane tubing (12 000–14 000 molecular mass
cut-off) and in Spectra/Por 6 wet tubing (25 000 molecular mass
cut-off), for separation of second polymer fractions also in
Spectra/Por 3 (6000 molecular mass cut-off). The operations were
conducted against frequently changed batches of magnetically
stirred H2O at specified pH. Size exclusion chromatography was
performed on Sephadex G-25. Polymer samples were dried in a
SARTORIUS Thermo Control Infrared Drying System (heating
program: 2 × 5 min at 65°C) or in an Abderhalden tube (2 d at
50°C) under reduced pressure.
Cell culture tests were performed over a 72-h period against
the CCRF CEM/S leukemic lymphoblasts cell line and its
resistant CCRF CEM/E sublime. SEM limits did not exceed 10%
from the mean in all tests. The protocol used has previously been
described.11
3.2. Solvents, Reagents, Monomeric Reactants
Deionized water was used for preparative, chromatographic,
and dialysis operations. N,N-Dimethylformamide (DMF) and
N-methylpyrrolidone (NMP), both predried over Molecular
Sieves 4A, were redistilled under reduced pressure in a gentle
stream of N2; the first 5% of distillate were discarded. All other
solvents, laboratory grade, were used as received, and so were
the coupling agents, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophosphate (HBTU) and 1-ethoxy-
carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), as well as
monomeric amines and other reactants (Fluka Chemie AG).
Methotrexate (+ amethopterin, MTX) was a gift from Dr J.
Kreisher, Theraplex Corporation; additional quantities were
purchased from Fluka Chemie.
3.3. Poly-DL-succinimide
This educt polymer was prepared as a master batch by the
procedure of Neri and Antoni,15 the mass-average molecular
mass derived from viscosity data16 was 34100. The polymer,
finely pulverized, was dried in an Abderhalden tube (1 d,
70–75°C) under reduced pressure.
3.4. MTX Conjugates
Amounts of conjugates and precursor polymers are given as
base moles and thus refer to the simplest recurring units defined
by structures 1 to 14 normalized to y = 1.
Conjugate 1. The preparation of 1 exemplifies MTX conjugation
with the aid of EEDQ coupling agent. The carrier serving as the
educt polymer for this conjugate, poly-,-DL-[N-(3-(dimethyl-
amino)propyl)aspartamide(95)-co-N-(3-aminopropyl)aspartam
ide(5)], was prepared by the established general procedure
for aminolytic ring opening in polysuccinimide. To the stirred
solution of polysuccinimide, 1.94 g (20 mmol) in 15 mL of DMF,
was added 3-(dimethylamino)propylamine, 1.941 g (19 mmol),
dissolved in 1 mL of DMF. The solution, saturated with N2 , was
stirred in the stoppered flask for 8 h at ambient temperature,
followed by dropwise addition to 1,3-diaminopropane, 222 mg
(3 mmol), predissolved in 15 mL of DMF, stirred and cooled in an
ice bath. Resaturated with N2 , the resulting solution was stirred
for 20 h in an ice bath and another 3 h at room temperature. Up to
this point, moisture access was strictly precluded to prevent
inadvertent hydrolytic imide ring opening that would generate
carboxylic acid side groups. Partial solvent removal under
reduced pressure (bath temperature <50°C) and precipitation
with excess Et2O-hexane (2:1) afforded a resinous product,
which was washed thoroughly with hot toluene and Me2CO for
removal of monomeric amine. Redissolved in 25 mL of H2O,
with pH adjusted to 7–8, the product was dialysed for 2 d in
Spectra/Por 4 and for another 2 d in Spectra/Por 6 tubing against
frequently changed, magnetically stirred batches of H2O. For the
last 6 h of the second dialysis step, the retentate pH was raised to
9 (aq. ammonia) for elimination of spurious N-protonation. The
tube contents were freeze-dried and post-dried, giving 2.05 g
(51.8%) of light cream-coloured carrier polymer as a water-
soluble solid.
1H NMR, /ppm (expected proton counts in brackets): 3.2, 39H
(40H; CONHCH2); 2.8–2.3, 78H (80H; NHCOCH2, CH2N(CH3)2 ,
CH2NH2); 2.2 110H (114H; CH3); 1.8, 40H (40H; CH2CH2CH2).
For drug conjugation, the carrier, 396 mg (0.1 mmol), was
dissolved in 8 mL of DMF. MTX, 56 mg (0.12 mmol), was added in
small portions with stirring, followed by the dropwise addition
by syringe of EEDQ, 30 mg (0.12 mmol), dissolved in 2 mL of
NMP, and triethylamine, 24 mg (0.24 mmol). The solution,
saturated with N2 , was stirred for 24 h at room temperature and
for another 0.5 h at 50°C. The conjugate was precipitated from
the cooled (5°C) solution with excess Et2O-hexane (2:1) and
redissolved in 20 mL of H2O. The solution, with pH adjusted to
10 (Na2CO3) in order to dissociate and remove unreacted MTX,
was passed through a column (1.5 × 15 cm) charged with
Sephadex G-25 and equilibrated with H2O at the same pH. The
eluate (exclusion volume) containing the light yellow product
band was dialysed for 2 d in Spectra/Por 6 tubing against H2O at
pH 6.8. For the last 6 h of this operation, the retentate pH was
reduced to 4 (0.1 M HCl) and, after several minutes, raised again
to 6 (aq. ammonia) in order to liberate the pendent carboxyl
group of the attached drug from its Na salt. The retentate was
freeze-dried to afford 270 mg (61.5%) of yellow, water-soluble 1.
1H NMR, /ppm: 8.6–6.6, with individual signals at 8.6, 7.7, and
6.8, 5.1H (1H + 2H + 2H = 5H; aromatic and heteroaromatic CH
of MTX); 1.7, 40H (40H; CH2CH2CH2). The data indicate 101%
MTX incorporation of available NH2 sites, corresponding to
10.4% by mass.
The combined outer phases collected in this dialysis operation
were redialysed for 2 d in Spectra/Por 3 tubing, and from the
retentate another portion, 92 mg (21%), of lower-molecular
conjugate was isolated as a yellow, water-soluble solid, NMR
data indicating an MTX content of 8.5% by mass.
Conjugate 2. In this coupling experiment, HBTU was used as
the coupling agent. The precursor polymer, poly-,-DL-[N-(3-
(dimethylamino)propyl)aspartamide(90)-co-N-(3-aminopropyl)
aspartamide(10)], was synthesized from polysuccinimide,
3-(dimethylamino)-propylamine, and 1,3-diaminopropane by a
previously described procedure.18 It was isolated as a water-
soluble solid in 51% yield.
1H NMR, /ppm: 3.25, 19H (20H; CONHCH2); 2.8–2.3, 39H
(40H; NHCOCH2, CH2N(CH3)2, CH2NH2); 2.2, 56H (54H; CH3);
1.75, 20H (20H; CH2CH2CH2).
For MTX conjugation, 196 mg (0.1 mmol) of the carrier was
dissolved in 4 mL of DMF together with MTX, 56 mg
(0.12 mmol). A solution of HBTU, 42 mg (0.11 mmol), in 0.5 mL of
DMF was added dropwise with stirring, followed by triethyla-
mine, 26 mg (0.26 mmol), and stirring of the N2-saturated solu-
tion was continued for 2 h at room temperature. The conjugate
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was precipitated and further worked up as described for conju-
gate 1, to give 135 mg (55%) of yellow, water-soluble 2.
1H NMR, /ppm: 8.6–6.5 combined, 4.85H (5H; aromatic and
heteroaromatic CH of MTX); 1.7–1.6, 20H (20H; CH2CH2CH2).
Thus, 97% of available NH2 is substituted by MTX, corresponding
to a drug content of 17.0% by mass.
In a repeat drug coupling experiment, only 87% of available
NH2 sites were substituted. The polymer was re-treated with 0.4,
0.3, and 0.8 equivalents of MTX, HBTU, and NEt3, respectively,
for 2.5 h at ambient temperature. Work-up as above gave conju-
gate for which NMR data indicated an MTX content of 18.6% by
mass.
Conjugate 3. The carrier polymer, poly-,-DL-[N-(3-(dimethyl
amino)propyl)aspartamide-(80)-co-N-(3-aminopropyl)asparta
mide(20)], was synthesized as described for the precursor to 1,
except with these reagent amounts: polysuccinimide, 20 mmol;
3-(dimethylamino)-propylamine, 16 mmol; 1,3-diamino
propane, 12 mmol; in a total of 35 mL of DMF. Yield, 47%.
1H NMR, /ppm: 3.3–3.2, 10.5H (10H; CONHCH2); 2.8–2.28,
18H (20H; NHCOCH2, CH2N(CH3)2, CH2NH2); 2.2, 26H (24H;
CH3); 1.7, 10H (10H; CH2CH2CH2).
The carrier so obtained was conjugated with MTX by the
procedure described for 2, except with the following mole ratio
of reactants and reagents in the feed:carrier, 0.3 mmol; MTX,
0.39 mmol; HBTU, 0.33 mmol; NEt3, 0.78 mmol. The yellow,
water-soluble conjugate 3 was obtained in a yield of 48%.
1H NMR, /ppm: 8.6–6.6 combined, 4.75H (5H; aromatic and
heteroaromatic CH of MTX); 1.7, 10H (10H; CH2CH2CH2). An
MTX incorporation of 95%, corresponding to 31.2% by mass, is
indicated by these data.
In repeat experiments (and similar coupling experiments
conducted at these reactant ratios in the feed) a faint precipitation
of solids was observed in the early stages of the reaction. The
addition of a few mL of hexamethylphosphoramide resulted in
clear solutions.
Conjugate 4. This conjugate, taken from the preceding investi-
gation,1 was redialysed (20 h in Spectra/Por 4) and isolated upon
freeze-drying as a water-soluble polymer. 1H NMR data indi-
cated 98% MTX incorporation, corresponding to 18.1% by mass.
In two repeat experiments, drug incorporation was 79 and
83%, requiring retreatment as described for conjugate 2. This
raised the figures to 93 and 95%, respectively, corresponding to
17.3 and 17.6% by mass.
Conjugate 5. The required carrier, poly-,-DL-[N-(3-
(dimethylamino)propyl)aspartamide-(95)-co-N-(3,6-diaza-
hexyl)aspartamide(5)], was prepared by the procedure leading
to the carrier required for 1, except that 1,3-diaminopropane was
replaced by the same amount (3 mmol) of diethylenetriamine.
The water-soluble polymer was isolated in 59% yield.
1H NMR,/ppm: 3.1, 42H (40H; CONHCH2); 2.8–2.2, 61H (64H;
NHCOCH2, CH2N(CH3)2, CH2NH(CH2)2NH2); 2.15, 117H (114H;
CH3); 1.7, 38H (38H; CH2CH2CH2).
MTX conjugation with the carrier so obtained, 399 mg
(0.1 mmol), was carried out as described for conjugate 1. This
gave 230 mg of light yellow, water-soluble 5.
1H NMR, /ppm: 8.6–6.8 combined 4.4H (5H; aromatic and
heteroaromatic CH of MTX); 1.8, 38H (38H; CH2CH2CH2). An
MTX incorporation of 88% of available NH2 is indicated by these
data.
The conjugate was retreated as described for 2 to give polymer
with 95% MTX incorporation, corresponding to 9.8% by mass.
Yield, 175 mg (39.8%).
Conjugates 6 and 7. Derived from the respective carriers,
poly-,-DL-[N-(3-(dimethylamino)-propyl)aspartamide(90)-
co-N-(3,6-diazahexyl)aspartamide(10)] and its (80)-(20) analog,
these conjugates had previously been described and were taken
from that investigation.1 Redialysis for 1 d in Spectra/Por 4 and
freeze-drying provided the conjugates with 101% and 95% MTX
incorporation, corresponding to 18.7 and 30.6% MTX by mass.
Conjugate 8. The required carrier, poly-,-DL-[N-(3- (dimethyl
amino)propyl)aspartamide-(90)-co-N-(3-amino-2-hydroxy
propyl)aspartamide(10)], was prepared in 54% yield from
polysuccinimide, 970 mg (10 mmol), dissolved in 8 mL of DMF,
3-(dimethylamino)-propylamine, 920 mg (9 mmol), in 3 mL of
DMF, and 1.3-diaminopropan-2-ol, 270 mg (3 mmol), in 8 mL of
DMF by the general procedure described for the preparation of
the precursor polymer of conjugate 1. Yield, 1.05 g (53.5%).
1H NMR, /ppm: 3.7, 1H (1H; CH2CH(OH)CH2); 3.2, 21H (20H;
CONHCH2); 2.9–2.1, 95H (94H; NHCOCH2, CH2N(CH3)2,
CH2NH2); 1.7, 18H (18H; CH2CH2CH2).
For MTX conjugation, the carrier, 198 mg (0.1 mmol), was
dissolved in 2 mL of DMF together with MTX, 57 mg
(0.125 mmol). HBTU, 47 mg (0.125 mmol), in 0.5 mL of DMF was
added dropwise to the stirred solution. Upon the further
addition of triethylamine 25 mg (0.25 mmol), the solution was
saturated with N2 and stirred for 2 h at room temperature.
Work-up as described for conjugate 1 gave 8 as a yellowish,
water-soluble solid in a yield of 110 mg (45.7%).
1H NMR, /ppm: 8.6–6.6 combined, 4.3H (5H; aromatic and
heteroaromatic CH of MTX); 1.8, 18H (18H; CH2CH2CH2). MTX
incorporation: 98%, corresponding to 18.5% by mass.
A repeat experiment provided 8 with 73% substitution of avail-
able NH2
Conjugate 9. This compound was taken from the preceding
investigation.1 It was redialysed for 1 d in Spectra/Por 4 tubing
and, after freeze-drying, was collected as a yellow, water-soluble
solid.
1H NMR, /ppm: 8.6–6.5 combined, 5H (5H; aromatic and
heteroaromatic CH of MTX); 3.6–3.2, 65H (65H; CH3OCH2,
CONHCH2). An MTX incorporation of 100% is inferred from
these data, corresponding to 20.8% by mass.
Conjugate 10. The precursor polymer, poly-,-DL-[N-
(2-hydroxyethyl)aspartamide(95)-co-N-(3,6-diazahexyl)
aspartamide(5)], was prepared in 43% yield as described for the
synthesis of the educt polymer for conjugate 1, except that
ethanolamine replaced 3-(dimethylamino)propylamine, and
diethylenetriamine was used in place of the diaminopropane,
both in the respective amounts.
1H NMR, /ppm: 3.7–3.6, 35H (38H; CH2OH); 3.4-3.3, 41H
(40H; CONHCH2); 3.0–2.5, 43H (46H; remaining CH2).
For drug conjugation, the carrier, 321 mg (0.1 mmol), was
dissolved in 4 mL of DMF. To the stirred solution was slowly
added MTX, 59 mg (0.13 mmol), a solution of HBTU, 49 mg
(0.13 mmol) in 2 mL of NMP, and NEt3 , 27 mg (0.27 mmol), in that
order. The stirred solution, saturated with N2 , was stirred for
2.5 h at ambient temperature. Precipitated and worked up as
before, the conjugate was obtained as a yellowish, water-soluble
solid in a yield of 240 mg (65%).
1H NMR, /ppm: 8.7–6.9 combined, 4.7H (5H; aromatic and
heteroaromatic CH of MTX); 3.7–3.6, 38H (38H; CH2OH). An
MTX incorporation of 94% is inferred from these data, corre-
sponding to a drug content of 11.6% by mass.
Conjugate 11. This conjugate was taken from the preceding
investigation.1 Redialysis for 1 d in Spectra/Por 4 tubing and con-
ventional work-up provided 11 as a yellow water-soluble solid.
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1H NMR, /ppm: 8.5–6.4 combined, 4.85H (5H; aromatic and
heteroaromatic CH of MTX); 3.6, 18H (18H; CH2OH). These data
indicate 97% MTX incorporation, corresponding to an MTX con-
tent of 21.5% by mass.
Conjugate 12. The precursor polymer, poly-,-DL-[N-(3,6-
dioxahexyl)aspartamide(95)-co-N-(3,6-diazahexyl)asparta-
mide(5)] was prepared in 53% yield by the method used for the
synthesis of the educt polymer for conjugate 1, except that
2-(2-aminoethoxy)ethanol and diethylenetriamine replaced
3-(dimethylamino)propylamine and 1,3-diaminopropane,
respectively. The water-soluble carrier was routinely isolated in
53% yield.
1H NMR, /ppm: 3.8–3.6, 114H (114H; O(CH2)2OCH2); 3.5-3.2,
44H (40H; CONHCH2); 3.0–2.5, 42H (46H; remaining CH2).
MTX conjugation was brought about by dissolving the carrier,
404 mg (0.1 mmol), in 4 mL of DMF, and adding MTX, 64 mg
(0.14 mmol), to the stirred solution. This was followed by the
addition of HBTU, 49 mg (0.13 mmol) in 2 mL of NMP, and NEt3,
28 mg (0.28 mmol). The resulting, N2-saturated solution was
stirred for 2.5 h at ambient temperature. Work-up by the conven-
tional procedure gave light-yellow, water-soluble conjugate 12
in a yield of 264 mg (59%).
1H NMR, /ppm: 8.6–6.8 combined, 4.95H (5H; aromatic and
heteroaromatic CH of MTX); 3.8–3.6, 114H (114H; O(CH2)2
OCH2). The data indicate 99% MTX incorporation, correspond-
ing to a drug content of 10.1%.
Conjugate 13. The precursor polymer, poly-,-DL-[N-(3.6-
dioxahexyl)aspartamide(90)-co-N-(3.6-diazahexyl)aspartamide(
10)], was taken from an earlier investigation,17 there designated
carrier 9. It was redialysed for 20 h in Spectra/Por 4 tubing and,
upon conventional work-up, was obtained as a beige-coloured,
water-soluble solid.
1H NMR, /ppm: 3.75–3.6, 54H (54H; O(CH2)2OCH2); 3.5–3.1,
21H (20H; CONHCH2); 3.0–2.5, 26H (26H; remaining CH2).
Initial drug-coupling experiments employing MTX/NH2 molar
ratios in the feed of 1.2–1.3 afforded conjugates with deficient
drug incorporation. This required a modification of the procedure.
Briefly, the carrier, 202 mg (0.1 mmol), dissolved in 3 mL of DMF,
was treated with MTX, 68 mg (0.15 mmol), a solution of HBTU,
53 mg (0.14 mmol), in 2 mL of NMP, and NEt3, 30.5 mg (0.3 mmol),
in that order. The N2-saturated solution was stirred for 2 h
at room temperature and worked up by the conventional proce-
dure. This gave yellow, water-soluble conjugate 13 in a yield of
169 mg (69%).
1H NMR, /ppm: 8.6–6.5 combined, 5H (5H; aromatic and
heteroaromatic CH of MTX); 3.8–3.5, 54H (54H; O(CH2)2OCH2).
The data indicate 100% MTX incorporation, corresponding to
18.5% by mass.
Conjugate 14. The precursor carrier, poly-,-DL-[N-(3.6-dioxa-
hexyl)aspartamide(90)-co-N-(3-aminopropyl)aspartamide(10)],
taken from an earlier project18 (there designated 11) was redia-
lysed for 1 d in Spectra/Por 6 tubing and isolated as a water-
soluble solid by the established procedure.
1H NMR, /ppm: 3.8–3.55, 53.5H (54H; O(CH2)2OCH2); 3.4–3.1,
20.5H (20H; CONHCH2); 2.9–2.4, 21H (22H; NHCOCH2,
CH2NH2); 1.8–1.7, 2H (2H; CH2CH2CH2).
The carrier, 199 mg (0.1 mmol), was conjugated with MTX,
59 mg (0.13 mmol), HBTU, 46 mg (0.12 mmol), and NEt3, 27 mg
(0.26 mmol), in 4 mL of DMF + 1 mL of NMP over a period of 2 h
at room temperature and conventional work-up. There was
obtained 149 mg (62%) of yellow, water-soluble 14.
1H NMR, /ppm: 8.6–6.5 combined, 4.75H (5H; aromatic and
heteroaromatic CH of MTX); 3.8–3.5, 54H (54H; O(CH2)2OCH2).
The data show 95% of MTX to be incorporated, corresponding to
a drug content of 18.0% by mass.
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